Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

Dose optimization is increasingly important in oncology, as exemplified by the US Food and Drug Administration ’s Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers, as well as patients and physicians in lo w- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective, and can be delivered at lower doses, resulting in less toxicity for patients, and lower costs for pati ents and payers.

Source: European Journal of Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Mark J. Ratain, Garth W. Strohbehn Source Type: research